All In Biotech

Drug Trial Radar · NCT07318155

A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease

A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of Subcutaneously Administered SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

104

Planned (sponsor's estimate)

Start

Mar 11, 2025

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Sirius Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Jan 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and/or peripheral arterial disease (PAD) with aspirin as background concomitant therapy.

Conditions

  • Coronary Artery Disease (CAD)
  • Peripheral Arterial Disease

Interventions

  • SRSD107Drug

    Administered S.C.

  • 0.9 % sodium chlorideDrug

    Administered S.C.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in time-averaged FXI antigenTime frame: 72 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fuwai Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.